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Abstract 
 
Background/Aim. Alveolar osteitis (AO), also known as “dry 
socket”, is relatively common post-extraction complication. It 
probably occurs due to excessive fibrinolytic activity in the co-
agulum and is characterized by intense pain sensations. The 
aim of this clinical study was to examine the role of hyaluronic 
acid and aminocaproic acid in the treatment of AO. Methods. 
The study included 60 patients with the clinical diagnosis of 
AO. All the patients were divided into two groups of 30 pa-
tients each according to the applied non-pharmacological 
measure: irrigation – irrigation of dry socket with sterile saline; 
curettage – careful curettage. Both of these groups were further 
divided into three subgroups regarding the applied treatment 
(hyaluronic acid; hyaluronic acid + aminocaproic acid; Alvo-
gyl®, an anesthetic and antiseptic paste), each with 10 patients, 
according to the following protocol: 0.2 mL of hyaluronic acid 
in the form of a 0.8% gel; 2 mL of aminocaproic acid and hya-
luronic acid;  Alvogyl®. During each visit, scheduled for every 
two days until complete absence of painful sensations, the pa-
tients had the therapeutic method repeated as at the first ex-
amination. At each control visit the number of present symp-
toms and signs of AO was recorded, as well as the level of pain 
(measured with a visual analogue scale). Results. With the use 
of hyaluronic acid, with or without aminocaproic one, a statisti-
cally significantly faster reduction in pain sensations was 
achieved, along with the reduction in the number of symptoms 
and signs of AO compared to the use of Alvogyl®. Conclu-
sion. Hyaluronic acid, applied alone or in combination with 
aminocaproic acid significantly reduces pain sensation, thus it 
can be successfully used in the treatment of AO. 
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Apstrakt 
 
Uvod/Cilj. Alveolitis je relativno česta postekstrakciona 
komplikacija. Nastaje, najverovatnije, usled izrazite 
fibrinolitičke aktivnosti u koagulumu, a karakteriše se pojavom 
intezivnog bola. Cilj ove kliničke studije bio je da se ispita 
mogućnost primene hijaluronske i aminokapronske kiseline u 
terapiji alveolitisa. Metode. Studija je uključila 60 pacijenata sa 
kliničkom dijagnozom alveolitisa. U odnosu na primenjenu 
nefarmakološku meru svi pacijenti su bili podeljeni u dve grupe 
sa po 30 pacijenata: ispiranje – ispiranje obolele alveole 
sterilnim fiziološkim rastvorom; kiretaža – pažljiva kiretaža. 
Obe ove grupe, u odnosu na primenjeni tretman [(hijaluronska 
kiselina, hijaluronska kiselina + aminokapronska kiselina, 
Alvogyl® (kombinacija anestetika i antiseptika u obliku paste)], 
bile su podeljene u tri podgrupe sa po 10 pacijenata po 
sledećem protokolu: 0,2 mL hijaluronske kiseline u obliku 0.8% 
gela; 2 mL aminokapronske kiseline i hijaluronske kiseline; 
Alvogyl®. Na kontrolnim pregledima, zakazanim na svaka dva 
dana do potpunog prestanka bolnih senzacija, pacijentima je 
ponavljana terapijska opcija sa prvog pregleda. Evidentiran je 
broj prisutnih simptoma i znakova alveolitisa kod pacijenata, 
kao i nivo bola (meren pomoću vizuelno-analogne skale). 
Rezultati. Primenom hijaluronske kiseline, sa ili bez 
aminokapronske kiseline, postignuto je statistički značajno brže 
sniženje bolnih senzacija kao i smanjenje broja prisutnih 
simptoma i znakova alveolitisa u odnosu na upotrebu 
Alvogyl®-a. Zaključak. Hijaluroska kiselina, samostalno ili u 
kombinaciji sa aminokapronskom kiselinom, značajno snižava 
bol, te se može uspešno primenjivati u terapiji alveolitisa. 
 
Ključne reči: 
zub, ekstrakcija; postoperativne komplikacije; 
alveolitis, suvi; hijaluronska kiselina; aminokapronske 
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Introduction 
Alveolar osteitis (AO) sometimes occurs after tooth 
extraction due to the disturbances in the healing processes. It 
is characterized by the appearance of postoperative pain in 
and around the extraction area, which increases from the first 
to the third post-extraction day, and is combined with partial 
or total destruction of a blood clot in the alveolus 1. AO de-
velops after 3–4% of all extractions, and even more often af-
ter surgical extraction of impacted lower third molars, up to 
around 30%. The incidence of AO is five times higher in 
women than in men and much higher in the lower jaw (10 
times more often after the extraction of the lower molars than 
of the upper ones) 2–4. AO is probably caused by excessive 
fibrinolytic activity in the post-extraction coagulum that le-
ads to destruction of the fibrin matrix and blood clot degra-
dation 5. 
The first symptoms of AO usually appear 1–3 days after 
extraction 6, 7 in the form of severe pain, taste disorder and 
bad breath. All reported cases were diagnosed in up to 7 days 
following extraction. The symptoms of AO are present, de-
pending on the aggressiveness of the disease, usually 5–10 
days 1. In the alveolus, there are either remains of a decom-
posed coagulum or the alveolus is empty, with exposed bone. 
The alveolus can be filled with food remains and the surro-
unding gingiva can be edematous and erythematous. Regio-
nal lymphadenopathy can be present 8. 
There were various approaches to the treatment of AO 
that involved the use of a wide range of resources, rinsing so-
lutions and procedures 2. These procedures were proposed 
for suppressing the symptoms of AO. On the average, it ta-
kes 7–10 days for the exposed bone to become covered with 
young granulated tissue. During this time it is necessary to 
make efforts in order to reduce subjective discomforts of the 
patient 9. Most commonly used for that purpose is Alvogyl® 
(Septodont, France), an anesthetic and antiseptic paste. 
Hyaluronic acid has anti-inflammatory and anti-
edematous potential which helps wound healing and increases 
the tissue elasticity 10–14. A pilot study conducted on rats 
showed that treatment of a dry socket with a preparation that 
contains 1% of hyaluronic acid resulted in rapid formation of 
coagulum and accelerated healing of post-extraction wound 15. 
Aminocaproic acid (epsilon-aminocaproic acid) is a po-
tent antifibrinolytic agent. It competitively blocks high 
affinity lysine receptors on the plasminogen proenzyme and 
thus prevents formation of a ternary complex with tissue pla-
sminogen activator (t-PA) and fibrin 16. For many years, the 
aminocaproic acid has been used in various fields of surgery 
(oral surgery, cardiac surgery) 17. 
The aim of this clinical study was to explore if 
hyaluronic and aminocaproic acid can be used successfully 
in the treatment of AO. 
Methods 
This prospective randomized clinical study was carried 
out in the period from 2011 to 2014 at the Department of 
Oral Surgery of the Faculty of Medicine, University of Priš-
tina, Kosovska Mitrovica, Serbia. All check-ups as well as 
surgical procedures were performed by one oral surgeon. 
The patients voluntarily participated in the study and were 
thoroughly familiarized with the principles of performing 
clinical research. The study was approved by the Ethic 
Committee of the Faculty of Medicine, University of Prišti-
na, Kosovska Mitrovica. 
The study included 60 patients of both sexes and of diffe-
rent age who, based on the anamnesis and clinical 
examination, were diagnosed with AO. The study included pa-
tients who had undergone tooth extraction and who came to 
check-up because of an onset of pain in and around the 
extraction region. The AO diagnosis was made in accordance 
with Blum’s 1 definition, based on the following clinical signs 
and symptoms: onset of pain from the first to the third post-
extraction day, the presence of a decomposed coagulum in the 
post-extraction alveolus or a bare alveolar bone. The study 
excluded patients who used antibiotics or analgesics after 
extraction, patients who previously received radiotherapy or 
chemotherapy, patients on anticoagulant therapy and patients 
with systemic diseases that influence the processes of healing 
of the post extraction wound (eg. diabetes mellitus, vascular or 
hematological disorders and other serious pathological lesions 
in the mouth). 
All the patients were randomly divided into two groups 
per 30 patients each according to the applied non-
pharmacological measure: irrigation – irrigation and medi-
cament; curettage – curettage and medicament. Dry sockets 
of the patients from the irrigation group were irrigated with 
20 mL of sterile saline (0.09% NaCl), which was enough to 
completely remove debris from the alveolus. Dry sockets of 
the patients from the curettage group were carefully curetted 
and a remotely healthy coagulum was preserved. Before cu-
rettage, local infiltration anesthesia, articaine with adrenaline 
(UbistesinTM forte, 3M ESPE AG, Germany), was adminis-
tered to patients.  
Furthermore, each of these two large groups was divided 
into three subgroups with 10 patients each regarding the used 
medicament: hyaluronic acid – irrigation (HA-I), hyaluronic 
acid + aminocaproic acid – irrigation (HA+AA-I) and 
Alvogyl® – irrigation (Alvogyl®-I); hyaluronic acid – curettage 
(HA-C), hyaluronic acid + aminocaproic acid – curettage 
(HA+AA-C) and Alvogyl® – curettage (Alvogyl®-C). Dry so-
ckets of the patients from the subgroups were then treated ac-
cording to the following protocol: HA-I and HA-C: 0.2 mL of 
hyaluronic acid in the form of a 0.8% gel (Gengigel® prof. - 
0.8% hyaluronic acid, Ricerfarma SRL, Milan, Italy); 
HA+AA-I and HA+AA-C: 2 ml of aminocaproic acid (Ami-
car®, XANODYNE PHARMACEUTICALS, INC, USA, am-
poule 250 mg/ml) and hyaluronic acid; Alvogyl®-I and 
Alvogyl®-C: Alvogyl® (Septodont, France). The patients were 
not given any other types of medicaments. 
The patients had scheduled control visits for every two 
days until complete absence of painful sensations. At every 
control visit, the patients had the therapeutic method repea-
ted as at the first examination. 
During each control visit the number of present symptoms 
and signs of AO was recorded for every patient. Marked as the 
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Table 1 
 Age and gender distribution of the patients with alveolar osteitis 
Gender, n (%) Treatment, n (%) Total Age 
(years) male female irrigation curettage n (%) 
> 30 8 (22.2) 7 (29.2) 7 (23.3) 8 (26.7) 15 (25) 
30–39 14 (38.9) 9 (37.5) 8 (26.7) 15 (50) 23 (38.3)
40–49 8 (22.2) 5 (20.8) 9 (30) 4 (13.3) 13 (21.7)
50–59 4 (11.1) 2 (8.3) 3 (10) 3 (10) 6 (10) 
≥ 60 2 (5.6) 1 (4.2) 3 (10) 0 (0) 3 (5) 
Total 36 (100) 24 (100) 30 (100) 30 (100) 60 (100) 
 
 
Table 2 
 Clinical symptoms and signs of the study groups that underwent irrigation (I) during follow-up 
Symptoms and signs of alveolar osteitis (AO) 
 Visit Patients’ group n Pain* Pain irradiation 
Swelling of the  
regional lymph nodes
Redness of 
the  
gingiva 
Halitosis
HA-I 3.3 10 8 5 4 6 
HA+AA-I 3 10 7 4 5 4 
1 
Alvogyl®-I 3.4 10 6 7 6 5 
HA-I 2.6 10 5 4 3 4 
HA+AA-I 2.7 10 6 5 4 2 
2 
Alvogyl®-I 3.4 10 6 7 6 5 
HA-I 1.7 7 4 2 2 2 
HA+AA-I 1.1 7 1 1 2 0 
3 
Alvogyl®-I 2 9 3 3 4 1 
HA-I 0.7 4 2 0 1 0 
HA+AA-I 0.6 4 0 0 2 0 
4 
Alvogyl®-I 1.3 7 2 1 3 0 
HA-I 0.1 1 0 0 0 0 
HA+AA-I 0.2 2 0 0 0 0 
5 
Alvogyl®-I 0.5 4 0 0 1 0 
symptoms and signs of AO were: pain, pain irradiation, swelling 
of the regional lymph nodes, redness of the gingiva around the 
extraction wound and halitosis. The presence of symptoms and 
signs was recorded in the “present” / ”not present” manner. The 
level of pain was determined (measured with a visual analogue 
scale – VAS, graded in centimetres from 0 to 10, where 0 was 
the lowest notch marking the “absence of pain” while notch 10 
marked “unbearable pain”). The total number of examinations 
was also recorded, to a complete cessation of painful sensations, 
for each individual patient. 
The data primarily obtained were analyzed with desc-
riptive statistical methods and methods for testing statistical 
hypotheses. From descriptive methods, measures of central 
tendency (ґ; median), measures of variability (SD, variation 
interval) and the relative numbers (structure indicators) were 
used. For testing the hypotheses, the methods used were: χ2 
test for testing the difference in frequency among the groups; 
Kruskal-Wallis and Mann-Whitney test for testing the diffe-
rences in value of the characteristics among the groups, Frie-
dman and Wilcoxon test for testing the changes in the value 
of the characteristics in time. The statistical hypotheses were 
tested at a significance level of 0.05. 
Results 
Of the total number of patients, 60% were male and 
40% female. There was no significant difference in the 
frequency of gender in the groups examined (χ2 = 0.278; SS 
= 1; p = 0.598). The mean age of patients in the groups was 
37.72 ± 10.91 (Table 1). 
At the first visit following tooth extraction, of all the 
determined symptoms and sings of AO, only pain was pre-
sent in all the patients. There was no difference in the avera-
ge number of present symptoms and signs of AO between 
the examined groups at the first and the second visit (p > 
0.05). A statistical significance existed among the subgroups 
of the Curettage group, where hyaluronic acid was applied, 
during the third, fourth and fifth visit in relation to the group 
Alvogyl-C (Tables 2 and 3).  
Regardless of the treatment, the scores on the VAS of pa-
in decreased during the follow-up period but there was a statis-
tical difference in pain levels among the groups (Table 4). 
Among the subgroups where hyaluronic acid was applied, 
with or without aminocaproic one, in relation to the subgro-
ups that were treated with Alvogyl®, a statistical difference 
HA – hyaluronic acid; AA – aminocaproic acid; n – average number of patients with symptoms and signs of AO. 
*Pain was estimated by visual analog scale (VAS): 0 – no pain; 10 – unbearable pain. 
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Table 3 
 Clinical symtoms and signs of the study groups that underwent curretage (C) during follow-up 
Symptoms and signs of alveolar osteitis (AO) 
Visit Patients’ group n Pain* Pain irradiation
Swelling of the  
regional lymph nodes
Redness of the  
gingiva Halitosis 
HA-C 3.4 10 8 6 5 5 
HA+AA-C 3.2 10 8 4 5 5 
1 
Alvogyl-C 3.4 10 7 6 7 4 
HA-C 2 8 4 4 2 2 
3 
2 
HA+AA-C 2.1 8 5 2 3 
3 Alvogyl-C 2.9 9 6 5 6 
0 HA-C 0.9† 6 1 0 2 
HA+AA-C 0.9† 7 0 0 0 
3 
Alvogyl-C 2.3 9 5 4 3 
2 
2 
0 HA-C 0.3† 2 0 1 0 
HA+AA-C 0.4 3 0 1 0 
4 
Alvogyl-C 1.1 7 2 1 1 
0 
0 
0 HA-C 0† 0 0 0 0 
HA+AA-C 0† 0 0 0 0 
5 
Alvogyl-C 0.3 3 0 0 0 
0 
0 
† – statistical significance compared to the Alvogyl® - C group (p = 0.05). For abbrevations see under Table 2. 
*Pain was estimated by visual analog scale (VAS): 0 – no pain; 10 – unbearable pain. 
 
Table 4 
Average level of pain estimated by visual analog scale (VAS)* in the patients  
with alveolar osteitis by the groups during follow-up visits 
 Irrigation (ґ ± SD)  Curettage (ґ ± SD) Visit 
HA-I HA+AA-I Alvogyl®-I HA-C HA+AA-C Alvogyl®-C 
1 7.3 ± 2.06 7.9 ± 1.66 7.4 ± 1.43 7.7 ± 1.49 7.9 ± 1.59 7.4 ± 1.65 
2 5.1 ± 2.51 5.1 ± 2.51 7.2 ± 1.34 3.8 ± 2.7 3.5 ± 2.32 6.1 ± 2.6 
2.4 ± 2.12† 2.4 ± 2.12† 5.1 ± 1.91 1.6 ± 1.5† 1.8 ± 1.8† 4.3 ± 2.5 3 
0.7 ± 1.1† 4 0.7 ± 1.1† 2.9 ± 1.9 0.3 ± 0.68† 0.6 ± 1.1† 2.1 ± 1.91 
5 0.2 ± 0.63 0.4 ± 0.84 0.8 ± 0.92 0† 0† 0.5 ± 0.85 
*VAS: 0 – no pain; 10 – unbearable pain; † – statistical significance compared to Alvogyl® 
group (p = 0.05); ґ – mean; SD – standard deviation. 
i 2 3
 
Table 5 
 Average number of visits up to the complete cessation of painful  
sensations by the groups during follow-up 
Group of patients ґ SD Med Min Max
HA-I   3.2† 1.03 3 2 5 
HA+AA-I   3.3† 0.95 3 2 5 
Alvogyl®-I 4.3 0.82 4.5 3 5 
  HA-C   2.6† 1.07 3 1 4 
HA+AA-C   2.8† 1.13 3 1 4 
Alvogyl®-C 3.9 1.1 4 1 5 
was noticed during the third, fourth and fifth visit. The pain 
levels were the same between the groups where hyaluronic 
acid was used and those treated with aminocaproic acid, as 
well.  
Comparison of the groups in relation to the average 
number of visits, up to a complete cessation of painful sensa-
tions, demonstrated similar results (Table 5). In the irrigation 
group, there was a statistically significant difference in the 
number of visits between the treatment subgroups HA-I and 
HA+AA-I compared to Alvogyl®-I, while in the curettage 
group, statistical significance existed between the treatment 
subgroups HA-C and HA+AA-C compared to Alvogyl®-C. 
Discussion 
The therapy of AO is symptomatic. It includes irrigation 
or curettage of the dry socket and topical use of different 
pharmacological and non-pharmacological packaging 18. By ir-
rigation with saline, food debris and remains of decomposed 
blood cloth are eliminated and the number of bacteria from the 
† – statistical significance compared to the Alvogyl® group (p = 0.05);  
ґ – mean; SD – standard deviation; Med – median; Min-max – minimal- 
maximal value. For abbrevations see under Tables 2 and 3. 
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socket reduced. A similar effect is achieved with curettage, 
but it is possible to provoke bleeding from the alveolar bone, 
which could enable the creation of a new, healthy blood clot. 
After the irrigation, ie curettage, topical packaging should 
suppress subjective discomfort of patients, up to the moment 
when the bare bone is covered with young granulated tissue. 
The idea to use hyaluronic acid in the treatment of AO 
stemmed from its proven qualities: analgesic, reparative and 
regenerative potential, high elasticity, biocompatibility, 
biodegradability and low immunogenicity 11, 19. 
The results of this study are consistent with the results 
obtained by McGregor 20 who states that AO usually occurs 
in the third and fourth decade of life. The results show that 
AO often occurs in the fifth decade of life, which coincides 
with the claims of some other authors 1. While the study was 
being conducted, there were no any patients of younger age 
(< 20 years old), so it can be concluded that in this age AO 
occurs only exceptionally. 
Even though some authors 21 state that AO occurs more 
frequently in the female population, no such results were ob-
tained in this study. 
Although the main goal in the treatment of AO is pain reli-
ef, it is very important to evaluate other, more objective, clinical 
parameters that will provide an unbiased comparison between 
the examined treatment methods. It is obvious that the promoti-
on of wound healing will lead to the reduction of painful sensa-
tions 22. The data obtained in this study indicate that hyaluronic 
acid significantly faster reduces the number of symptoms and 
signs of AO compared to relatively frequent use of Alvogyl®. 
The best results were gained within the group with curettage 
performed and followed by the use of hyaluronic acid. 
The main and most discomforting symptom of AO is se-
vere pain. All the treatment methods investigated in this study 
decreased the level of pain, but there was a statistically signifi-
cant difference in pain level throughout the examination period 
between the patients treated with hyaluronic acid and those 
treated with Alvogyl®. In all the groups of patients treated with 
hyaluronic acid a faster reduction of pain level was achieved 
comparing to Alvogyl® groups. 
With the introduction of aminocaproic acid, followed 
by hyaluronic acid in the treatment of AO in this study, the 
expected positive results were not obtained. There was no 
statistically significant difference in terms of the reduction of 
subjective discomfort of patients whose painful alveoli were, 
besides with hyaluronic acid, treated with aminocaproic acid, 
as well. This coincides with some previous studies in which 
there were attempts to reduce the incidence of AO with local 
application of tranexamic acid (TXA), a potent antifibrinolytic, 
but with little or no sucsess 23, 24. 
All the results gained in this study prove that hyaluronic 
acid has a positive influence on the healing process of dry 
socket, but the exact mechanism of its actual role is yet to be 
investigated. Based on the results of this study and the avai-
lable literature, it might be possible to suppose the following: 
when the dry socket is curetted and bleeding is provoked, a 
new blood clot may be created; hyaluronic acid placed into 
this new wound will act as a coagulum stabilizer, preventing 
its uneven and excessive degradation; during the first phase 
of wound healing, the fibrin threads form a web that repre-
sents a matrix for the platelet clot formation, followed by a 
production of hyaluronic acid (by simulating different 
inflammatory mediators, especially interleukin –β and plate-
let-derived growth factor); the molecules of hyaluronic acid 
penetrate the fibrin matrix and stimulate cell migration, 
particularly the fibroblast from the surrounding tissue, and 
the production of new collagen; 25–29 additional amount of 
hyaluronic acid in this way probably stabilizes coagulum and 
has a positive effect on the wound healing. 
If the alveolus affected with AO is rinsed with saline 
until the complete removal of debris, and then hyaluronic 
acid is applied to it, other positive qualities of hyaluronic 
acid will come to the fore. Namely, anti-inflammatory, anti-
edematous and analgesic potential of hyaluronic acid will 
contribute to wound healing and, consequently, lower pain 
sensations. One of the advantages of local application of 
hyaluronic acid is reflected in its adhesive properties which 
allow its positive qualities to establish healthy coagulum for 
a longer period of time 30. Covering completely the bare al-
veolar bone, hyaluronic acid represents a barrier to irritant 
influences of external substances. 
Conclusion 
The obtained results confirm the hypothesis that 
hyaluronic acid can be successfully used in the treatment of 
alveolar osteitis in the manner in this study described. 
Hyaluronic acid application accelerates the reduction of pa-
inful sensations, and also reduces the number of symptoms 
and signs of alveolar osteitis compared to the use of 
Alvogyl® alone. 
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